RNA Supply Chain Resources

  1. Expectations On The Pathway To GMP For Gene-Modified Cell Therapies 6/21/2023

    Learn how a robust understanding of the RNP’s critical process parameters and CQAs is crucial for ensuring product consistency, enhancing patient safety, and maintaining regulatory compliance.

  2. A Novel RNA Lipid Nanoparticle Platform: Gene-Edited CAR T Cells For Off-The-Shelf Cancer Therapy 4/14/2022

    We report on the use of a novel lipid nanoparticle (LNP) reagent in a validated protocol to achieve successful complex gene editing in primary T cells with high efficiency while maintaining high cell viability.

  3. Demystifying CRISPR gRNA Chemical Modifications 10/28/2024

    Chemical modifications on CRISPR gRNAs enhance stability, editing efficiency, and reduce immune responses, enabling in vivo applications and clinical success.

  4. CRISPR sgRNA For Successful Gene Editing: Discovery To Clinic 9/25/2023

    The single guide RNA (sgRNA) is one of the key components of successful CRISPR gene editing. Here we cover all the important aspects of sgRNA and Synthego’s sgRNA products.

  5. Enabling CDMOs To Focus On Core Priorities 4/26/2024

    Explore innovative solutions for CDMO's striving to remain competitive as the biopharmaceutical market grows and evolves.

  6. Consolidating The Supply Chain For mRNA 2/12/2024

    Learn about the first end-to-end cGMP facility that was developed for mRNA manufacturing to address the shortage of CDMOs and the inadequate and inefficient supply chain options for sourcing GMP mRNA.

  7. Novel Lipid Nanoparticle Delivery Reagent And Manufacturing Workflow 4/18/2022

    We aim to highlight that commercially available LNP reagent mix, GenVoy-ILM, is an accessible and easy-to-use LNP formulation that allows for rapid preclinical development of RNA vaccines.

  8. Transitioning From Using RUO To cGMP Chemicals For Clinical Trials 10/17/2023

    Learn about the common challenges and risks associated with accelerating your molecule's timeline from lab to clinic, along with important supply chain considerations for emerging biopharma companies.